Fundraising Fox
Bridgebio
Founded 2014 · 1,034 employees on LinkedIn · 7 known investors
Find your way into Bridgebio
Sign up to find every way you can get introduced to Bridgebio
- Your email: who you already know at Bridgebio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Bridgebio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Investors · 7
How we know: Aisling Capital's portfolio page · Not right? Tell us
How we know: Frazier Life Sciences's portfolio page · Not right? Tell us
How we know: HEALTHCARE ROYALTY PARTNERS's portfolio page · Not right? Tell us
How we know: Longwood Fund's portfolio page · the VCSheet dataset · Not right? Tell us
Founder mafia
3 people who came through Bridgebio went on to found or lead other companies.
Frequently asked questions
- What does Bridgebio do?
- BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
- Who are Bridgebio's investors?
- Bridgebio's investors include Aisling Capital, Amzak Health, EcoR1 Capital, Frazier Life Sciences, HEALTHCARE ROYALTY PARTNERS, Longwood Fund, Sequoia Capital.